Literature DB >> 11198507

Nasal midazolam effects on childhood acute seizures.

T Fişgin1, Y Gürer, N Senbil, T Teziç, P Zorlu, C Okuyaz, D Akgün.   

Abstract

Sixteen children, aged from 2 months to 14 years, with a diagnosis of acute seizures and seen at Dr. Sami Ulus Child Health and Disease Center, were included in this study. Midazolam (5 mg/mL) 0.2 mg/kg was administered intranasally in 30 seconds by an injector. The heart rate, respiratory rate, blood pressure, and oxygen saturation were recorded at 0, 5, and 10 minutes after administration. The seizures of three (18.7%) patients terminated within 1 minute, of seven (43.7%) patients in 1 to 2 minutes, and of three (18.7%) patients in 2 to 5 minutes. However, three (18.7%) patients did not respond to treatment. As a result, it was concluded that intranasal midazolam administration is easy and effective. The half-life of midazolam is shorter than diazepam, and midazolam has fewer complications when compared with diazepam. It is easier to use in nasal drop and spray forms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11198507     DOI: 10.1177/088307380001501219

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  7 in total

1.  Treatment of acute seizures: is intranasal midazolam a viable option?

Authors:  Lesley K Humphries; Lea S Eiland
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

Review 2.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 3.  Potential new methods for antiepileptic drug delivery.

Authors:  Robert S Fisher; Jet Ho
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Intranasal midazolam compared with intravenous diazepam in patients suffering from acute seizure: a randomized clinical trial.

Authors:  Mohsen Javadzadeh; Kourosh Sheibani; Mozhgan Hashemieh; Hedyeh Saneifard
Journal:  Iran J Pediatr       Date:  2012-03       Impact factor: 0.364

5.  Intranasal Midazolam versus Rectal Diazepam for the Management of Canine Status Epilepticus: A Multicenter Randomized Parallel-Group Clinical Trial.

Authors:  M Charalambous; S F M Bhatti; L Van Ham; S Platt; N D Jeffery; A Tipold; J Siedenburg; H A Volk; D Hasegawa; A Gallucci; G Gandini; M Musteata; E Ives; A E Vanhaesebrouck
Journal:  J Vet Intern Med       Date:  2017-05-24       Impact factor: 3.333

6.  Nasal and buccal treatment of midazolam in epileptic seizures in pediatrics.

Authors:  Ayşe Ulgey; Recep Aksu; Cihangir Bicer
Journal:  Clin Med Insights Pediatr       Date:  2012-07-24

7.  Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: A multi-center randomized parallel group clinical study.

Authors:  Marios Charalambous; Holger A Volk; Andrea Tipold; Johannes Erath; Enrice Huenerfauth; Antonella Gallucci; Gualtiero Gandini; Daisuke Hasegawa; Theresa Pancotto; John H Rossmeisl; Simon Platt; Luisa De Risio; Joan R Coates; Mihai Musteata; Federica Tirrito; Francesca Cozzi; Laura Porcarelli; Daniele Corlazzoli; Rodolfo Cappello; An Vanhaesebrouck; Bart J G Broeckx; Luc Van Ham; Sofie F M Bhatti
Journal:  J Vet Intern Med       Date:  2019-10-03       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.